Your trusted source for investing success
Novo Nordisk today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for semaglutide, a glucagon-like peptide-1 analog administered once-weekly, for the treatment of adults with type 2 diabetes.
On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014, also referred to as the Safe Harbour rules.
Novo Nordisk has today announced its intention to reduce its workforce by approximately 1,000 employees of the 42,300 positions in the company’s global organisation.
Swedish Orphan Biovitrum today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development.
FenoLogica Biosciences Inc., a Seattle-WA-based life sciences company, announces completion of a licensing and collaboration agreement with the Pacific Northwest Research Institute (PNRI). FenoLogica also announces closing of its seed investment round that took place on June 13, 2016.
FenoLogica’s technology combines novel quantitative biology measurement techniques with cloud-based analytical tools
According to iData Research’s report entitled, “European Market Report Suite for Diabetes Diagnosis, Treatment and Drug Delivery”, market growth is fueled by the prevalence of diabetis in Europe and advancements in technology, especially in the test strip and pen needle segments.
As quoted in the report:
Pen needles are reimbursed under healthcare
How is the Brexit referendum affecting the UK’s biotech and life sciences sectors?
First-in-class anti-MICA/B therapeutic antibody;
New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation;
IND-enabling studies starting in 2016.
MARSEILLE, France, April 18, 2016 (GLOBE NEWSWIRE) — Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH) today presented a new set of preclinical data further validating
XOMA Corporation (NASDAQ:XOMA) has reported that the company has exclusively licensed the global development and commercialization rights to its XMetA program of allosteric monoclonal antibodies. These antibodies up-regulate the insulin receptor to Novo Nordisk A/S.
Novo Nordisk (NYSE:NVO) has come up against the challenge of a volatile foreign exchange environment. CEO Lars Rebien Sorensen has suggested that perhaps a new insulin production plant in the U.S. may offer a viable solution to this problem.
